neurorx and relief therapeutics announce enrollment of 150 patients in phase 2b/3 trial of rlf-100 for critical covid-19 with respiratory failure
neurorx and relief therapeutics announce enrollment of 150 patients in phase 2b/3 trial of rlf-100 for critical covid-19 with respiratory failure
since july 2020, more than 210 patients with critical covid-19 and respiratory failure have been treated with rlf-100 under fda-approved protocols.